PharmGen Science, Inc.

004720KOSPIPharmaceuticals

PharmGen Science, Inc. (004720, KOSPI) reported KRW 173bn revenue in 2025.

Reported financials

Figures are as filed with the Korean regulator, in billions of won (KRW bn). We do not convert to dollars — an exchange rate would be a number we made up, not one the company reported.

YearRevenueOperating profitNet profitAssetsEquityBasis
2021110-532220127Consolidated
2022151770317207Consolidated
202316796336228Consolidated
2024171113363249Consolidated
20251736-117195146Separate

Ratios, year by year

Each ratio is computed inside its own year. A dash means the input was missing or the denominator was zero — not that the value is zero.

YearOperating marginNet marginEquity / assetsReturn on equity
2021-4.6%29.5%57.6%25.5%
20225%46.4%65.3%33.8%
20235.5%3.4%67.9%2.5%
20246.2%1.6%68.6%1.1%
20253.5%-67.4%74.9%-79.7%

Revenue moved 57.5% between 2021 and 2025.

Net profit was negative in the 1 most recent year on file. Counted from the 5 years in which the company filed a net-profit line — a year with no filing is skipped, not read as a loss.

These are arithmetic, not judgements. We do not say whether a margin is good or bad, and we do not rank companies against each other.

Market size

Market capitalisationKRW 68bn
Close priceKRW 3,000
Listed shares22,654,365
Price as of20260909

Market capitalisation is what buyers are betting the company is worth. It is not something the company produced, so we never present it as output or productivity.

When it was founded

The incorporation date on the company's registration record, as filed with Korea's Financial Supervisory Service. This is when the company was legally formed — not when it first listed, and not when the business it grew out of began trading.

Incorporated

Who runs it

Registered representative directors — in Korea this is the office a CEO holds. Filed with the Financial Supervisory Service (DART). A Korean company can register more than one, and the title beside each name is the rank they carry inside the company.

NameTitleBoard seatYears in post
Kim Hye-yeon (김혜연)Representative Director (CEO)Inside director13 years
Park Hui-deok (박희덕)Representative Director (CEO)Inside director12 years

Roman spellings are ours, converted from the Korean filing. The person may spell their own name differently in English. The Korean name in brackets is what was filed.

Workforce — a side measure, not the main one

Employees (2025)229
Women80 (34.9%)
Average tenure8.1 years
Annual pay, menKRW 77,318,000
Annual pay, womenKRW 60,212,000
Pay ratio, women to men77.9%

Other companies in Pharmaceuticals

181 listed companies file under this classification. Showing 12.

See the whole Pharmaceuticals list →